Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05190705 · ClinicalTrials.gov registry record · Phase 2
Loncastuximab Tesirine in WM
A Phase 2 study of Waldenstrom Macroglobulinemia, sponsored by Shayna Sarosiek, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT05190705 is a Phase 2 study of Waldenstrom Macroglobulinemia that is actively recruiting participants, run by Shayna Sarosiek, MD. The registered enrollment target is 36 participants, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05190705, a Phase 2 study of Waldenstrom Macroglobulinemia, is actively recruiting participants, sponsored by Shayna Sarosiek, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is being done to examine the safety and effectiveness of loncastuximab tesirine as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The name of the study drug involved in this study is: * Loncastuximab tesirine
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Loncastuximab Tesirine
Study Locations (4)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
Minnesota
- Mayo Clinic - Rochester
Washington
- Fred Hutch - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-02-17 |
| Est. Completion | 2028-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05190705
The ClinicalTrials.gov registry entry for NCT05190705 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (92% lower). The listed sponsor is Shayna Sarosiek, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT05190705 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Minnesota, Washington.
Frequently Asked Questions
What is clinical trial NCT05190705 about?
NCT05190705 is a clinical study titled "Loncastuximab Tesirine in WM". This study is being done to examine the safety and effectiveness of loncastuximab tesirine as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The name of the study drug involved in this study is: * Loncastuximab tesirine
What is the current status of trial NCT05190705?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2022-02-17. Estimated completion is 2028-08-01.
What conditions does trial NCT05190705 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia.
What interventions are being tested in trial NCT05190705?
The interventions under investigation include: Dexamethasone (DRUG), Loncastuximab Tesirine (DRUG).
Who is sponsoring clinical trial NCT05190705?
This trial is sponsored by Shayna Sarosiek, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05190705 being conducted?
This trial has 4 study locations across Massachusetts, Minnesota, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
Epcoritamab in Previously Treated WM
RECRUITING · Phase 2
-
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
RECRUITING · Phase 2
-
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
RECRUITING · Phase 2
-
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RECRUITING · Phase 2
-
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.